Navigation Links
Cryoablation -- A new treatment option for some kidney tumor patients

ce in percutaneous RFA led the researchers to recognize that it has two important limitations. Tumors larger than 3 centimeters are difficult to treat with RFA, with increased rates of technical failures and tumor recurrence. Also, the area being treated cannot be effectively monitored with computed tomography (CT) or ultrasound. The Mayo study findings show that cryoablation can be used for some larger tumors with simultaneous operation of multiple cryoprobes guided by ultrasound. The ablation margin (the edge of the frozen tissue) can be accurately monitored with CT, to ensure that the total tumor mass is treated.

The researchers reviewed the records of the 23 men and 17 women with kidney cancer treated with percutaneous cryoablation at Mayo Clinic between March 12, 2003, and Aug. 4, 2005. They found that this treatment was chosen over RFA for reasons such as larger tumor size, proximity of tumor to ureter or bowel, or a central location on the kidney. Cryoablation was successful in 38 of the 40 patients, with no repeat treatment necessary.

In percutaneous cryoablation, one or more hollow needles are inserted through the skin directly into a tumor. Doctors can observe and guide the insertion by combined use of ultrasound and CT. The needle, or cryoprobe, is filled with argon gas, which results in rapid freezing of the tissue to temperatures of -100° C; and the tissue is then thawed by replacing the argon with helium. The procedure consists of two freezing and thawing cycles, seeking a frozen margin of approximately 5 millimeters beyond the tumor edge to ensure death of the entire tumor. After the cryoprobes are removed, small bandages are placed over the skin puncture sites, and the patient spends one night in the hospital before returning home.

Surgeons continue to seek less invasive methods than the traditional radical nephrectomy (removal of cancerous kidney) for the treatment of small tumors, and percutaneous cryoablatio
'"/>

Source:Mayo Clinic


Page: 1 2 3

Related biology news :

1. Protein discovery could unlock the secret to better TB treatment
2. Topical treatment shown to inhibit HIV and herpes simplex virus infection
3. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
4. Researchers add new tool to tumor-treatment arsenal
5. Potential treatments for neurofibromatosis
6. Nanoparticles offer new hope for detection and treatment
7. Technique may allow cancer patients to freeze eggs, preserving fertility before starting treatment
8. PET/CT can identify new cancer lesions at early stage, allowing for prompt treatment
9. New understanding of DNA repair may pave way to cancer treatments
10. Multiple-drug resistant gene expression pattern predicts treatment outcome for pediatric leukemia
11. Newer imaging techniques may lead to over-treatment

Post Your Comments:
(Date:12/2/2009)..., , REDWOOD SHORES, Calif. and PALM...mmunication Intelligence Corporation ("CIC") (OTC ...ronic signature solutions for business process aut...zed leader** in biometric signature verification a...nternational Electronic Document Management (EDM) ...
(Date:12/2/2009)..., Single-walled nanotubescylinders of carbon about...r potential applications such as ultrastrong fiber...gen storage components for fuel cells. Thanks to a...stitute of Standards and Technology (NIST) and fiv...e list: detection and destruction of an aggressive...
(Date:12/2/2009)..., A scientist from the University of Salamanca and...presence of predators affects the behaviour of Ac...m the Negev Desert in the Near East. According to ... mobile and different prey if they are under press...d predicted this result, but until now there had b...
Breaking Biology News(10 mins):CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 2CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 3CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 4Combining nanotubes and antibodies for breast cancer 'search and destroy' missions 2Lizards change their diet to avoid predators 2Isis Pharmaceuticals to Present at the 2009 Canaccord Adams Cardiovascular Conference 5940 1MarketsandMarkets 3A Global Stem Cell and Advanced Technologies Market Worth US 24 88 3 Billion By 2014 14699 1MarketsandMarkets 3A Global Stem Cell and Advanced Technologies Market Worth US 24 88 3 Billion By 2014 14699 2MarketsandMarkets 3A Global Stem Cell and Advanced Technologies Market Worth US 24 88 3 Billion By 2014 14699 3Medical Device Software Engineering Firm Full Spectrum Software Appoints Cindy Larkin to Director of Client Services 14697 1Medical Device Software Engineering Firm Full Spectrum Software Appoints Cindy Larkin to Director of Client Services 14697 2
...n Molecular Biology Organization (EMBO) announced ... young researchers as the 2007 beneficiaries of it...h year since 2000, the programme identifies and su.... Recipients receive academic, practical and finan... independent careers. , Selected by EMBO Members...
...t. 22 Emphysema patients whose lungs are implante...l valve experience significantly improved measures...e, University of Pittsburgh School of Medicine res...CHEST 2007, the annual meeting of the American Col...inue through Thursday, Oct. 25, at the McCormick P...
...en elderly nursing home residents contract pneumon...Simin Nikbin Meydani, DVM, PhD of the Jean Mayer U...fts University and colleagues report that maintain...ay help reduce the risk of pneumonia development i...rs that daily zinc intake can help nursing home re...
Other Biology News:18 young scientists join EMBO Young Investigator network 2Endobronchial valve significantly improves emphysema 2Zinc may reduce pneumonia risk in nursing home elderly 2
(Date:12/2/2009)...c. 2 S*BIO Pte Ltd today announced...or, SB1518, at The American Society of Hematology ... ,, Data will be presented on the clinical resu...18 detailing its safety, tolerability and pharmaco...vels ranging from 100 to 600 mg. These doses were ...
(Date:12/2/2009)...cientist, a leading scientific magazine covering t...e “Intelligent” EMCCD camera fourth am...ons of 2009. , (PRWEB) De... from Photometrics ®, a designer and manufac...r the life sciences, was ranked fourth among The S...
(Date:12/1/2009).... 1 Reportlinker.com announces tha... catalogue: ,, Industrial Enzymes - A Global M...0164431/Industrial-Enzymes---A-Global-Market-Repor...opoly with few strong players and a host of small ... competition and commoditization characterize the ...
(Date:12/1/2009)... 1 /PRNewswire-Asia/ -- Shanghai ChemPartner, as t...hina-based Contract Research,Organization (CRO), t...,Technology Fast 50 China, ranking 3rd on the list...na. The award is a testament to ChemPartner,s outs...8. , The results of the 2009 Deloitte Tec...
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 2The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 3Reportlinker Adds Industrial Enzymes - A Global Market Report 2Reportlinker Adds Industrial Enzymes - A Global Market Report 3Reportlinker Adds Industrial Enzymes - A Global Market Report 4Reportlinker Adds Industrial Enzymes - A Global Market Report 5Reportlinker Adds Industrial Enzymes - A Global Market Report 6Reportlinker Adds Industrial Enzymes - A Global Market Report 7Reportlinker Adds Industrial Enzymes - A Global Market Report 8Reportlinker Adds Industrial Enzymes - A Global Market Report 9Reportlinker Adds Industrial Enzymes - A Global Market Report 10Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 2Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 3
...ed corticosteroid inhaler approved ... Aug. 19 Schering-Plough,Corporation (NYSE: SGP ...0,mcg (mometasone furoate inhalation powder) is no...ndicated for the maintenance treatment of asthma a...ge and older, and is the,first and only once-daily...
...c., a,leader in human embryonic stem cell derived ... an exclusive worldwide technology licensing agree...ation that will enable the,company to commercializ...ity of Georgia., (Logo: http://www.newscom.com/c...rms of the agreement, ArunA has acquired an exclus...
... ,endometrial regenerative cells, (ERCs) are capab...dvanced peripheral artery disease. A study publish...f Translational Medicine demonstrates that when ci...tions, circulation and functionality were restored... peripheral artery disease, causes approximately 1...
Other Biology Technology:Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11 2Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11 3Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11 4Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11 5Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11 6Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11 7Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11 8ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells 2Limbs saved by menstrual blood stem cells 2
Cytomics FC 500 Series Flow Cytometry Systems from Beckman Coulter
... can provide custom microplate coating using advan...g equipment that dispenses and washes a variety of...any lot size of the following formats (with a volu...ips, 96 well microplate, 384 well microp...
Mynox Mycoplasma Elimination Reagent from Minerva Biolabs GmbH
Coating Solution Concentrate Kit from KPL
Biology Products: